that are being simultaneously presented at the American Heart Association’s 2024 Scientific Sessions. JACC is publishing two secondary analyses on the impact of GLP-1 medications in improving cardiac ...
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced new results from the Phase 3 PALISADE study and the open-label extension from the Phase 2 MUIR and SHASTA-2 studies of investigational ...
Vir Biotechnology, Inc. today announced positive results from the SOLSTICE Phase 2 clinical trial evaluating tobevibart alone, or in combination with elebsiran, in people with chronic hepatitis delta ...